Literature DB >> 24973118

Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.

Judes Poirier1, Justin Miron2, Cynthia Picard2, Patrick Gormley2, Louise Théroux2, John Breitner2, Doris Dea2.   

Abstract

The discovery that the apolipoprotein E (apoE) ε4 allele is genetically linked to both sporadic and familial late-onset Alzheimer's disease (AD) raises the possibility that a dysfunction of the lipid transport system could seriously affect lipid homeostasis in the brain of AD subjects. The presence of the ε4 allele has been associated with lower levels of apoE in both serum and brain tissues of normal and AD subjects. In an attempt to reverse the apoE deficit in AD, we identified and characterized several apoE inducer agents using a low-throughput in vitro screening assay. The most promising of these compounds is called probucol. Administration of probucol, an old cholesterol-lowering drug, in a pilot trial in mild-to-moderate sporadic AD led to a significant increase in cerebrospinal fluid (CSF) apoE levels and a decrease in CSF in both phosphorylated tau 181 and beta-amyloid 1-42 concentrations without significant modifications of lipid hydroperoxide levels.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Apolipoprotein E; Cholesterol; Genetics; Lipids; Probucol; Statins

Mesh:

Substances:

Year:  2014        PMID: 24973118      PMCID: PMC5140289          DOI: 10.1016/j.neurobiolaging.2014.03.037

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  78 in total

1.  Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.

Authors:  V B Gupta; S M Laws; V L Villemagne; D Ames; A I Bush; K A Ellis; J K Lui; C Masters; C C Rowe; C Szoeke; K Taddei; R N Martins
Journal:  Neurology       Date:  2011-03-22       Impact factor: 9.910

2.  Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice.

Authors:  S Chapman; T Sabo; A D Roses; D M Michaelson
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

3.  Evolution of the human lifespan, past, present, and future: phases in the evolution of human life expectancy in relation to the inflammatory load.

Authors:  Caleb E Finch
Journal:  Proc Am Philos Soc       Date:  2012-03

4.  Apolipoprotein E mutants, hyperlipidemia and arteriosclerosis.

Authors:  G Utermann
Journal:  Adv Exp Med Biol       Date:  1985       Impact factor: 2.622

5.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

6.  Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: role of the astroglial response.

Authors:  D Champagne; J Rochford; J Poirier
Journal:  Exp Neurol       Date:  2005-07       Impact factor: 5.330

7.  Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice.

Authors:  Danúbia B Santos; Kaite C Peres; Renata P Ribeiro; Dirleise Colle; Alessandra A dos Santos; Eduardo L G Moreira; Diogo O G Souza; Cláudia P Figueiredo; Marcelo Farina
Journal:  Exp Neurol       Date:  2011-12-08       Impact factor: 5.330

8.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

9.  Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats.

Authors:  V Annapurna; I Senciall; A J Davis; K M Kutty
Journal:  Diabetologia       Date:  1991-05       Impact factor: 10.122

10.  The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.

Authors:  David R Riddell; Hua Zhou; Thomas A Comery; Evguenia Kouranova; C Frederick Lo; Helen K Warwick; Robert H Ring; Yolanda Kirksey; Suzan Aschmies; Jane Xu; Katie Kubek; Warren D Hirst; Catherine Gonzales; Yi Chen; Erin Murphy; Sarah Leonard; Dmytro Vasylyev; Aram Oganesian; Robert L Martone; Menelas N Pangalos; Peter H Reinhart; J Steve Jacobsen
Journal:  Mol Cell Neurosci       Date:  2007-01-25       Impact factor: 4.314

View more
  39 in total

1.  Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.

Authors:  Christian Henker; Thomas Kriesen; Katharina Fürst; Deborah Goody; Änne Glass; Brigitte M Pützer; Jürgen Piek
Journal:  J Neurooncol       Date:  2015-11-25       Impact factor: 4.130

Review 2.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

3.  Association between Cholesterol Exposure and Neuropathological Findings: The ACT Study.

Authors:  Brianne M Bettcher; M Colin Ard; Bruce R Reed; Andreana Benitez; Amanda Simmons; Eric B Larson; Josh A Sonnen; Thomas J Montine; Ge Li; C Dirk Keene; Paul K Crane; Dan Mungas
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Analysis of pleiotropic genetic effects on cognitive impairment, systemic inflammation, and plasma lipids in the Health and Retirement Study.

Authors:  Michael W Lutz; Ramon Casanova; Santiago Saldana; Maragatha Kuchibhatla; Brenda L Plassman; Kathleen M Hayden
Journal:  Neurobiol Aging       Date:  2019-03-06       Impact factor: 4.673

5.  Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain.

Authors:  Chia-Chen Liu; Jin Hu; Chih-Wei Tsai; Mei Yue; Heather L Melrose; Takahisa Kanekiyo; Guojun Bu
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

6.  Cumulative lead exposure is associated with reduced olfactory recognition performance in elderly men: The Normative Aging Study.

Authors:  Rachel Grashow; David Sparrow; Howard Hu; Marc G Weisskopf
Journal:  Neurotoxicology       Date:  2015-06-26       Impact factor: 4.294

7.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.

Authors:  Robert J Baranello; Krishna L Bharani; Vasudevaraju Padmaraju; Nipun Chopra; Debomoy K Lahiri; Nigel H Greig; Miguel A Pappolla; Kumar Sambamurti
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

8.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

9.  Subcellular Changes in Bridging Integrator 1 Protein Expression in the Cerebral Cortex During the Progression of Alzheimer Disease Pathology.

Authors:  Stephanie L Adams; Kathy Tilton; James A Kozubek; Sudha Seshadri; Ivana Delalle
Journal:  J Neuropathol Exp Neurol       Date:  2016-06-26       Impact factor: 3.685

Review 10.  Molecular Targets of Cannabidiol in Neurological Disorders.

Authors:  Clementino Ibeas Bih; Tong Chen; Alistair V W Nunn; Michaël Bazelot; Mark Dallas; Benjamin J Whalley
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.